{"title": "Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage", "doi": "10.1101/2020.02.10.20021584", "citation_id": "2020.02.10.20021584v1", "date": "2020-02-12", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.10.20021584", "abstract": "<p>Background: Severe ill patients with 2019 novel coronavirus (2019-nCoV) infection progressed rapidly to acute respiratory failure. We aimed to select the most useful prognostic factor for severe illness incidence.\nMethods: The study prospectively included 61 patients with 2019-nCoV infection treated at Beijing Ditan Hospital from January 13, 2020 to January 31, 2020. Prognostic factor of severe illness was selected by the LASSO COX regression analyses, to predict the severe illness probability of 2019-CoV pneumonia. The predictive accuracy was evaluated by concordance index, calibration curve, decision curve and clinical impact curve.\nResults: The neutrophil-to-lymphocyte ratio (NLR) was identified as the independent risk factor for severe illness in patients with 2019-nCoV infection. The NLR had a c-index of 0.807 (95% confidence interval, 0.676-0.38), the calibration curves fitted well, and the decision curve and clinical impact curve showed that the NLR had superior standardized net benefit. In addition, the incidence of severe illness was 9.1% in age \u2265 50 and NLR &lt; 3.13 patients, and half of patients with age \u2265 50 and NLR \u2265 3.13 would develop severe illness. Based on the risk stratification of NLR with age, the study developed a 2019-nCoV pneumonia management process.\nConclusions: The NLR was the early identification of risk factors for 2019-nCoV severe illness. Patients with age \u2265 50 and NLR \u2265 3.13 facilitated severe illness, and they should rapidly access to intensive care unit if necessary.</p>", "twitter_description": "Background: Severe ill patients with 2019 novel coronavirus (2019-nCoV) infection progressed rapidly to acute respiratory failure. We aimed to select the most useful prognostic factor for severe illness incidence. Methods: The study prospectively included 61 patients with 2019-nCoV infection treated at Beijing Ditan Hospital from January 13, 2020 to January 31, 2020. Prognostic factor of severe illness was selected by the LASSO COX regression analyses, to predict the severe illness probability of 2019-CoV pneumonia. The predictive accuracy was evaluated by concordance index, calibration curve, decision curve and clinical impact curve. Results: The neutrophil-to-lymphocyte ratio (NLR) was identified as the independent risk factor for severe illness in patients with 2019-nCoV infection. The NLR had a c-index of 0.807 (95% confidence interval, 0.676-0.38), the calibration curves fitted well, and the decision curve and clinical impact curve showed that the NLR had superior standardized net benefit. In addition, the incidence of severe illness was 9.1% in age \u2265 50 and NLR < 3.13 patients, and half of patients with age \u2265 50 and NLR \u2265 3.13 would develop severe illness. Based on the risk stratification of NLR with age, the study developed a 2019-nCoV pneumonia management process. Conclusions: The NLR was the early identification of risk factors for 2019-nCoV severe illness. Patients with age \u2265 50 and NLR \u2265 3.13 facilitated severe illness, and they should rapidly access to intensive care unit if necessary.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNone.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe data used to support the findings of this study are available from the corresponding author upon request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.10.20021584.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.10.20021584v1", "access_rights": "restricted", "authors": ["Jingyuan Liu", "Yao Liu", "Pan Xiang", "Lin Pu", "Haofeng Xiong", "Chuansheng Li", "Ming Zhang", "Jianbo Tan", "Yanli Xu", "Rui Song", "Meihua Song", "Lin Wang", "Wei Zhang", "Bing Han", "Li Yang", "Xiaojing Wang", "Guiqin Zhou", "Ting Zhang", "Ben Li", "Yanbin Wang", "Zhihai Chen", "Xianbo Wang"]}